Key Facts about Biotherapeutics
Biotherapeutics — also known as biologicals or biologic drugs — are therapeutic products derived from living cells rather than chemical synthesis. They include monoclonal antibodies (mAbs), recombinant proteins, viral vectors, vaccines and cell-based therapies, all engineered to act with the molecular precision of natural biological systems. Their defining feature is structural complexity: while a small-molecule drug such as aspirin contains around 21 atoms, a typical IgG antibody is a multi-domain glycoprotein of more than 25,000 atoms whose three-dimensional fold and post-translational modifications are inseparable from its therapeutic function.
Because biotherapeutics are produced by living cells, the bioreactor provides the precisely controlled environment in which cellular processes can run reproducibly, making it the central enabler of safe, consistent, GMP-compliant biotherapeutic production.
The biology of biotherapeutics
Understanding biotherapeutics begins with their biology. Unlike small-molecule drugs, biologics rely on the natural language of proteins, cells and immune effector functions.
-
Living cells are the production platform
Mammalian Chinese hamster ovary (CHO) cells dominate therapeutic protein production thanks to their ability to perform human-like post-translational modifications, while microbial hosts such as E. coli and yeast are used for simpler proteins, peptides and viral vector components.
-
Antibody architecture defines function
A therapeutic IgG antibody is built from two heavy and two light chains forming a Y-shaped molecule with two antigen-binding (Fab) regions and one effector-function (Fc) region. The Fab arms determine target specificity, while the Fc region governs immune mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
-
Glycosylation is a critical quality attribute
IgG antibodies carry a conserved N-glycan at asparagine 297 (Asn297) in the Fc region. Its composition directly modulates Fcγ-receptor binding, ADCC potency, thermal stability, half-life and immunogenicity — making glycan profile control one of the central goals of bioprocess development.
-
Cell physiology drives process design
Productivity and product quality are governed by cellular parameters such as viable cell density, specific productivity and metabolic state. Bioreactor parameters — temperature, pH, dissolved oxygen, agitation and feeding strategy — are tuned to keep cells in their optimal physiological window.
Biotherapeutics processing innovations
Biotherapeutics manufacturing has evolved from traditional batch and fed-batch operations toward intensified, continuous and digitalised bioprocesses. The driving idea behind process intensification is biological: keep cells healthy and metabolically active for longer, at higher densities and closer to their physiological optimum.
-
N-1 perfusion and intensified fed-batch
Coupling a perfused N-1 seed bioreactor with a high-inoculation-density production stage delivers reported titer increases of approximately 85% and space–time yield gains over 130% in CHO-based mAb production.
-
Continuous perfusion processing
Alternating tangential flow (ATF) and acoustic cell retention enable culture durations of weeks to months at very high cell densities, maintaining cells in a steady physiological state and improving product consistency.
-
Single-use bioreactor technology
Pre-sterilised single-use bioreactors reduce cleaning validation, shorten changeover and lower contamination risk, and have become a default for clinical-scale mAb, viral vector and vaccine production.
-
Cell line and digital engineering
CRISPR-Cas9-based gene editing and AI-supported bioprocess modelling enable tailored production hosts and predictive process control, accelerating the path from clone selection to clinical manufacturing.
Applikon bioreactor types for biotherapeutics
The Applikon bioreactor portfolio offered by Resea Biotec covers the complete development and production landscape for biotherapeutics — from early process screening in mini-scale vessels to large-scale GMP production in stainless steel systems. A consistent design philosophy across scales simplifies scale-up and ensures harmonised control of critical bioprocess parameters throughout the workflow.
| Bioreactor | Volume range | Vessel type | Operation mode | Application in biotherapeutics |
|---|---|---|---|---|
| Applikon MiniBio | 250 mL – 1000 mL | Glass (autoclavable) | Batch, Fed-batch | High-throughput clone screening, media optimisation, early process development for mAbs, recombinant proteins and viral vectors |
| Applikon Autoclavable Glass Bioreactor | 2 – 20 L | Glass (autoclavable) | Batch, Fed-batch, Perfusion | Bench-scale process development and scale-up for CHO-based mAb production, recombinant proteins and vaccine antigens |
| Applikon AppliFlex ST | 500 mL – 15 L | Single-use (3D-printed, pre-sterilised) | Batch, Fed-batch, Perfusion | Flexible, contamination-controlled workflows; seed train expansion; clinical-grade mAb, viral vector and vaccine production |
| Applikon Stainless Steel Bioreactor | Pilot to production scale | Stainless steel (CIP/SIP) | Batch, Fed-batch, Perfusion, Continuous | Large-scale GMP-compatible manufacturing of monoclonal antibodies, recombinant proteins, viral vectors and vaccines |
Challenges and future outlook
As biologic pipelines diversify beyond classic mAbs into bispecific antibodies, antibody–drug conjugates, cell and gene therapies and RNA-based therapeutics, manufacturing platforms must deliver greater biological flexibility, more reliable product quality and tighter control over cellular performance.
-
Open challenges
Cell line productivity and long-term phenotypic stability; consistent control of post-translational modifications such as glycosylation; bioprocess heterogeneity caused by gradients in dissolved oxygen, pH and shear during scale-up; and downstream bottlenecks created by intensified upstream titers.
-
Future outlook
Continuous and intensified bioprocesses — particularly N-1 perfusion and fully continuous upstream operations — are expected to become the new standard, supported by perfusion-adapted cell lines and advanced cell retention technology. Glycoengineering, synthetic biology and CRISPR-based host cell design enable tailored production cells with optimised metabolism, while AI-driven bioprocess modelling accelerates the timeline from discovery to clinical manufacturing.
Advanced Bioreactors for Biotherapeutic Manufacturing
State-of-the-art control systems allow for careful regulation of all critical parameters — including temperature, pH, dissolved oxygen levels, and agitation — ensuring the optimal environment for cell growth and product formation throughout the entire bioprocess.
Whether you’re a researcher, entrepreneur, or industry professional, our Applikon bioreactor technology empowers you to explore and innovate in the field of cell culture and biotherapeutics production.
